2010, Number 1
Rev Invest Clin 2010; 62 (1)
Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer
Hernández-Jardines A, Molina B, del Castillo V, Papadakis M, Rivera T, Azorín J, Herrera LA, Yokoyama E, Frías S
PDF size: 82.32 Kb.
We evaluated the chromosomal aberration (CA) frequencies
in the peripheral blood lymphocytes of ten female patients,
age average 43.7 ± 12.9, with thyroid cancer (TC) who had
been exposed to 100-200 mCi therapeutic doses of 131
blood samples were obtained before-treatment and at 2 and 24
h after-treatment. Radiation was measured in the samples by
means of dysprosium-activated calcium sulfate thermoluminescent
dosimetry. The maximum radiation levels were detected
in the samples taken 2 h after treatment. A positive
correlation was found between the sample-emitted radiation
values and the frequencies of CAs (r = 0.495; p ‹ 0.01). The
average baseline frequency of aberrations found in the ten
studied patients was 0.009 per cell. Upon application of the
I therapeutic dose, this frequency increased to 0.04 and 0.02
CAs/cell at 2 and 24 h after-treatment, respectively (p ‹ 0.05).
Break-type aberrations experienced a peak at 2 h after-treatment,
whereas rejoined aberrations, such as dicentrics, rings,
and radial figures, increased with sampling time. Seven
patients with metastases had high amounts of CAs at 2 and
24 h after-treatment, in comparison to three patients without
metastases who had a lower frequency of CAs at 24h aftertreatment.
This difference could be due to the fact that circulating
lymphocytes were exposed to a greater cancerous tissue
mass, which retains 131
I during the diagnostic and therapeutic
processes. These results demonstrate the importance of detecting
and surgically removing the largest possible amount
of thyroid tissue in order to diminish the exposure of normal
cells to radiation.
Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. Low vs. High Radioiodine Activity to Ablate the Thytoid after Thyroidectomy for Cancer: a Randomized Study, PloS. ONE. 3 (2008): e1885.
Black BM, Wooner LB, Blackburn CM. The Uptake of radioactive iodine by carcinoma of thyroid gland: a study of 128 cases. J Clin Endocrinol Metab 1953; 13: 1378-90.
Doi SA, Woodhouse NJ, Thalib L, Onitilo A. Ablation of the Thyroid Remnant and I-131 Dose in Differentiated Thyroid Cancer: a Meta-Analysis Revisited. Clin Med Res 2007; 5: 87-90.
Jonklaas J. Role of radioactive iodine for adjuvant therapy and treatment. J Natl Compr Canc Netw 2007; 5: 631-40.
Brill AB, Stabin M, Bouville A, Ron E. Normal Organ radiation dosimetry and associated uncertainties in nuclear medicin, with emphasis on iodine-131. Radiat Res 2006; 166: 128-40.
Raza H, Khan AU, Hameed A, Khan A. Quantitative evaluation of salivary gland dysfunction after radioiodine therapy using salivary gland scintigraphy. Nucl Med Commun 2006; 27: 495-9.
Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. Complications, sequela and dosimetry of iodine 131 therapy for thyroid carcinoma. J Nucl Med 1992; 33: 2214-21.
Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, et al. A Systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 2008; 69: 479-90.
Krassas GE, Perros P. Thyroid disease and male reproductive function. J Endocrinol Invest 2003; 26: 372-80.
Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 1994; 35: 1418-22.
Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17: 1277-88.
Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol 1994; 65: 7-17.
Moore RC, Bender MA. Time sequence of events leading to chromosomal aberration formation. Environ Mol Mutagen 1993; 22; 208-13.
Livingston GK, Foster AE, Elson HR. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes. J Toxicol Environ Health 1993; 40: 367-75.
Willegaignon J, Malvestiti LF, Guimaraes MI, Sapienza MT, Endo IS, Neto GC, et al. 131I effective half-life (Teff) for patients with thyroid cancer. Health Phys 2006; 91: 119-22.
Ardito G, Lamberti L, Bigatti P, Cottino F. Comparison of chromosome aberration frequency before and after administration of 131I in two groups of thyroid cancer patients, Tumori 1987; 73: 257-62.
Baugnet-Mahier L, Lemaire M, Léonard E, Léonard A, Gerber G. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer. Radiat Res 1994; 140: 429-31.
Monteiro GO, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E, et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 2000; 15: 69-75.
Boyd E, Buchanan W, Lennox B. Damage to chromosomes by therapeutic doses of radioiodine. The Lancet 1961; 277: 977-8.
Ramírez MJ, Puerto S, Galofré P, Parry EM, Parry JM, Creus A, et al. Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis 2000; 21: 1581-6.
Gundy S, Katz N, Füzy M, Ézik O. Cytogenetic study of radiation burden in thyroid disease patients treated with external irradiation or radioiodine. Mutat Res 1996; 360: 107-13.
Joseph LJ, Bhartiya US, Raut YS, Kand P, Hawaldar RW, Nair N. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis. Mutat Res 2009; 675: 35-40.
Im M, Lee JK, Hong YJ, Hong SI, Kang HJ, Na II, et al. Four cases of hematologic malignancy following radioactive iodine therapy for thyroid cancer. Korean J Lab Med 2008; 28: 425-29.